SI-BONE has posted a perfect 4-quarter earnings beat streak and holds a strong Piotroski score, but quality sits below the engine's floor on a failed Rule of 40 test, the V9 panel hard-blocks on a death cross, and both short interest and insider selling point to bearish positioning.
Thesis pillars
- Quality Below Floor Rule Of 40 Fail↓Deteriorating
- Death Cross Hard Block↓Deteriorating
- Perfect Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
SI-BONE, Inc. (SIBN) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $18.95: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 13%; Below-average business quality.
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the... Read more
Sell if holding. Engine safety override at $18.95: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 87d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-08-14Recent Developments — SI-BONE, Inc.
Latest news
- NEWS UBS Maintains Buy on SI-BONE, Raises Price Target to $25 — benzinga Aug 4, 2026 positive
- NEWS Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23 — benzinga Aug 4, 2026 positive
- NEWS TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20 — benzinga Aug 4, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga Aug 3, 2026 neutral
- NEWS SI-BONE Raises FY2026 Sales Guidance from $230.000M-$233.000M to $231.000M-$233.000M vs $231.775M Est — benzinga Aug 3, 2026 positive
Generated 2026-08-14T12:42:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -6.9%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.95: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $17.62. Score 5.5/10, moderate confidence.
Take-profit target: $21.75 (+14.8% upside). Prior stop was $17.62. Stop-loss: $17.62.
Quality below floor (3.4 < 4.0); Value-trap signals (2/5): Revenue declining (-7.6% YoY), Margin compression (op margin -142.6%).
SI-BONE, Inc. trades at a P/E of N/A (forward -57.3). TrendMatrix value score: 6.6/10. Verdict: Sell.
16 analysts cover SIBN with a consensus score of 4.2/5. Average price target: $25.
What does SI-BONE, Inc. do?SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in...
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.